Thomas Jefferson University

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University System of Maryland

Icahn School of Medicine at Mount Sinai

Christoph Wirblich

Matthias Johannes Schnell

Lisa E Hensley

Reed F Johnson

Drishya Kurup

Christopher M Coleman

Gene Tan

Matthew B Frieman

Christine Rettew Fisher

Matthew S Frieman

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

Multivalent vaccines for rabies virus and coronaviruses

The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

Coronavirus disease (COVID-19) vaccine

The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.

Compositions and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies

Growing community of inventors

Philadelphia, PA, United States of America

Christoph Wirblich